At the news
? BULLISHIMPACT 5/10 6-K filed Jun 1, 2026 at 07:00 ET
Kamada announced FDA approval of its new in-house RFFIT laboratory for rabies potency testing, which supports the manufacturing of KEDRAB and KAMRAB. The lab is expected to improve operational efficiencies and reduce reliance on external testing for its leading rabies franchise, which generated over $70 million in 2025 sales.
- FDA approved Kamada's new in-house RFFIT laboratory for rabies virus neutralization testing.
- The lab is located at Kamada's Beit Kama, Israel plant and is one of a limited number worldwide capable of such tests.
- The lab was also approved by Health Canada and the Israeli Ministry of Health prior to FDA approval.
- In 2025, Kamada's sales of KEDRAB and KAMRAB totaled over $70 million.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access